(Total Views: 346)
Posted On: 09/04/2019 10:25:05 AM
Post# of 149066
Just to clarify, my "what ever sticks" comment is what this LOOKS like, not what I think is going on. We know Leronlimab works and CCR5 is the key to many indications.
Other small biotechs adopt a plan of throwing out potential indications to try and milk out some value when the drug they have is not really that impressive. They are creating a lot of sizzle on the steak, because the steak is not that great.
It is tough to feel that these large number of huge indications are not a distraction from just focusing on HIV. However if the very real potential is there - why not? Especially since HIV is basically just waiting on the FDA.
Other small biotechs adopt a plan of throwing out potential indications to try and milk out some value when the drug they have is not really that impressive. They are creating a lot of sizzle on the steak, because the steak is not that great.
It is tough to feel that these large number of huge indications are not a distraction from just focusing on HIV. However if the very real potential is there - why not? Especially since HIV is basically just waiting on the FDA.
(2)
(0)Scroll down for more posts ▼
